Previous Close | 1.0400 |
Open | 0.9800 |
Bid | 0.9350 x 100 |
Ask | 1.0900 x 100 |
Day's Range | 0.9800 - 1.0100 |
52 Week Range | 0.7400 - 11.9100 |
Volume | |
Avg. Volume | 54,762 |
Market Cap | 6.685M |
Beta (5Y Monthly) | -0.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALZN
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). "Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades," said Stephan Jackman, Chief Executive Officer of Alzamend. "If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug m
ATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD
ATLANTA, November 20, 2023--Alzamend Gets FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive Disorder